Nanoform Q2 FY26 EBITDA loss narrows to EUR 3 million; revenue rises 16% to EUR 0.8 million

• Nanoform posted Q2 revenue up 16% to EUR 0.8 million, while EBITDA loss narrowed to EUR 3 million.
• Total operating costs fell 36% to EUR 3.9 million; basic EPS improved to EUR -0.04.
• Cash at June 30, 2026 was EUR 19 million; cash position declined EUR 1.5 million during the quarter.
• Operating free cash flow improved to EUR -3.4 million; employees fell 38% year over year to 108.
• UK MHRA scientific advice supported a hybrid pathway for nanoenzalutamide; first market authorization application targeted before end-2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanoform Finland plc published the original content used to generate this news brief on August 20, 2026, and is solely responsible for the information contained therein.